Absci Shares Are Trading Higher After the Company Highlighted Progress and Updates Across Its Proprietary Pipeline and Leading AI Platform on 2024 R&D Day. Its Drug Candidate Was Selected for ABS-201, an Anti-PRLR Antibody in Development for...
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated